Every major player in your health system gets a direct line to the industry’s most-needed insights and
the support to take action. Learn more.
Our research programs are role-specific to provide the exact insights and resources
that will make your job easier. We offer research for:
Get comprehensive access to Advisory Board research and tools on every topic we cover. Explore this option.
Create an account
Why medical and commercial leaders need to align on evidence strategy to meet customer demands
Driven by the Covid-19 pandemic, a new hunger for insight has spiked the appetite for real-world evidence across our industry.
Regulators have turned to RWE in the search for an effective Covid-19 treatment and to pass new emergency use approvals. Innovative payers and providers now use data sources once considered “untested” (e.g., wearable devices, smartphone diagnostic tools) to collect evidence about their populations, understand symptom progression, and better detect at-risk individuals. While HTAs are increasingly incorporating RWE into value assessments to inform price and access decisions.
And don’t be mistaken. This hunger is here to stay.
You must strengthen your evidence generation strategies now to meet these growing demands or fall behind adaptive competition. Yet optimizing internal RWE strategies and functions is easier said than done. Covid-19 has not erased the evidence generation challenges faced before. You must then go beyond the status quo of piecemeal RWE efforts and cross-functional collaboration to overcome legacy data and operational silos, and to improve efficacy and impact of RWE studies.
Advisory Board’s Madhavi Kasinadhuni is moderating a cross-functional panel of RWE leaders from Amgen, Takeda, Vertex, and Sanofi during a webinar on September 24. Attendees will learn:
Managing Director of Healthcare Ecosystem Research
Connect with Madhavi on LinkedIn
Many leaders are doubling down on investments in a wide array of data sources—such as EHRs, wearables, and tech platforms—to develop robust clinical evidence to answer critical questions regarding Covid-19.
Download our free resource as we outline five new data sources that clinical leaders are turning to, to answer five key Covid-19 questions.
For more than 40 years, we've helped executives and future leaders in health care work smarter and faster by providing provocative insights, actionable strategies, and practical tools to support execution.
With 40+ years of experience, a team of 250+ experts, and a network of 4,900+ member organizations that span the payer, provider, and supplier industries, we support life sciences firms’ commercial and medical leaders with research and educational resources that develop market strategy, enrich customer insight, and more.
→ More for life sciences medical leaders
→ More for health care suppliers and service firms